Previous 10 | Next 10 |
-- Jyseleca ® Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today an...
-- Jyseleca ® Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET ...
Japan's Ministry of Health, Labor and Welfare has approve Gilead's (GILD) Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of rheumatoid arthritis ((RA)) who did not respond to conventional therapies.Gilead will hold the mark...
Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials Mechelen, Belgium; 25 September 2020, 08.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co.,...
Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials Mechelen, Belgium; 25 September 2020, 08.00 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., L...
Led by subscription right exercises, Galapagos (NASDAQ: GLPG ) announced a share capital increase; it issued 86,280 new ordinary shares for a total capital increase (including issuance premium) of €2.4M. More news on: Galapagos NV, Healthcare stocks news, Read...
Amyris Inc. suffers a setback over patent lawsuit Amyris Inc. ( AMRS ) has been hit by a patent lawsuit instituted by Lavvan Inc. The $881 million lawsuit has been filed in the United States District Court for the Southern District of New York. Both the companies had inked a Research, Coll...
Vascular Biogenics (NASDAQ: VBLT ) +32% on strong preclinical results of MOSPD2 program. More news on: Vascular Biogenics Ltd., Genetic Technologies Limited, Eastman Kodak Company, Stocks on the move, , Read more ...
Galapagos (NASDAQ: GLPG ) perks 8% premarket on heels of positive topline results in the Phase 2a NOVESA trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc), a severe autoimmune disease. The trial enrolled 33 p...
I held on to my shares of Gilead Sciences (NASDAQ: GILD) for a long time. When sales for the big biotech's hepatitis C franchise sank a few years ago, pulling the stock down along the way, I stayed the course. When Gilead's seemingly promising nonalcoholic steatohepatitis (NASH) candidate s...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...